1
|
Gonzalez G, Cassaglia PD, Penas F, Martinez NL, Bettazza C, Wilensky L, Fontana Estevez F, Noli Truant S, Miksztowicz V, Cevey A, Cicale E, Berg G, Fernandez M, Goren N, Morales C. P6297Genetic mutation of galectin-3 altered the temporal evolution of macrophage polarization and healing affecting the post myocardial infarct remodeling in mice. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0895] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Background
Myocardial infarction (MI) is a dynamic process that leads to ventricular remodeling (VR) and largely to heart failure (HF). Previous studies established that Galectin-3 (Gal-3) is highly increased in the infarct zone from the beginning of MI and also that it is a prognostic marker of HF.
Purpose
We aimed to study the effects of genetic deletion of Gal-3 on macrophage (MΦ) infiltration, cytokines expression, fibrosis and MMP-2 activity as well as VR and function after MI in mice.
Methods
Male C57BL/6J and Gal-3 KO mice were subjected to permanent coronary ligature or sham. At 1 week post-MI LV function and VR were studied by echocardiography. We also studied in the infarct zone: 1) F4/80+ MΦ infiltration by flow cytometry; 2) M2 macrophage polarization by detection of mannose receptor (MR) and chitinase-3-like protein-3 (YM1) phenotype markers by rt-qPCR; 3) mRNA expression of TNF-α, IL-6, IL-10 and TGF-β; 4) MMP-2 activity by zymography and 5) fibrosis by histology.
Results
Results are expressed as X±SEM; *p<0.05 C57 MI vs Gal-3 KO MI. After 1 week post-MI, the pulmonary congestion assessed by the lung weight/body weight ratio (mg/g) was 9±0.4, 8±0.5 and 9±0.4 in C57 sham, Gal-3 KO sham and C57 MI, respectively, nevertheless it was severely increased to 15±1.2* in infarcted Gal-3 KO mice. MΦ infiltration, cytokine expression and MMP-2 activity in the infarct zone are shown in the table.
Table 1 Groups F4/80+ MR YM1 TNF-α IL-6 IL-10 TGF-β MMP-2 MΦ (%) (A.U.) (A.U.) (A.U.) (A.U.) (A.U.) (A.U.) (A.U.) C57 MI 5.6±0.9 (8) 0.5±0.2 (3) 1.7±0.4 (3) 26±0.3 (3) 1.7±0.5 (3) 0.7±0.03 (3) 1.8±0.5 (3) 1±0.1 (5) Gal-3 KO MI 2.6±0.4* (8) 1.8±0.4*(8) 4.2±0.4* (8) 0.4±0.5* (8) 6.7±0.9 * (8) 2.8±0.3 * (8) 0.5±0.2 * (8) 2±0.4* (6) A.U.: Arbitrary units. In MR, YM1, TNF-α, IL-6, IL-10 and TGF-β represent mRNA expression. In MMP-2 represent gelatinolytic activity. Number of samples is shown between parentheses.
After 1 week post-MI, LV end diastolic dimension was increased from 4.4±0.1 to 4.8±0.2* at the same time that ejection fraction (%) was significantly reduced from 47±2 to 38±3* in C57+MI (13) and Gal-3 KO+MI (16) respectively. Collagen concentration in the infarct zone was significantly reduced from 30±1.2% (6) to 17±0.5* % (8) in C57 and Gal-3 KO respectively.
Conclusion(s)
Gal-3 is an essential regulatory factor for the early wound healing since it regulates the dynamics of the reparative process through the phenotypic profile of MΦ, the pro- and anti-inflammatory cytokines expression and fibrosis along the temporal evolution of MI in mice. The deficit of Gal-3 diminished the infiltration of MΦ altering its phenotypic polarization and consequently, the dynamics of the wound healing as well as aggravating the functional and structural evolution of cardiac remodeling.
Acknowledgement/Funding
Argentine Agency for Promotion of Science and Technology (PICT 2014-2320), University of Buenos Aires (UBACyT 20020170100619BA)
Collapse
Affiliation(s)
- G Gonzalez
- University of Buenos Aires-CONICET. Faculty of Medicine, Institute of Cardiovascular Pathophysiology, Pathology, Capital Federal, Argentina
| | - P D Cassaglia
- University of Buenos Aires-CONICET. Faculty of Medicine, Institute of Cardiovascular Pathophysiology, Pathology, Capital Federal, Argentina
| | - F Penas
- University of Buenos Aires, Institute of Biomedical Research in Retrovirus and Aids, Capital Federal, Argentina
| | - N L Martinez
- University of Buenos Aires-CONICET. Faculty of Medicine, Institute of Cardiovascular Pathophysiology, Pathology, Capital Federal, Argentina
| | - C Bettazza
- University of Buenos Aires-CONICET. Faculty of Medicine, Institute of Cardiovascular Pathophysiology, Pathology, Capital Federal, Argentina
| | - L Wilensky
- University of Buenos Aires-CONICET. Faculty of Medicine, Institute of Cardiovascular Pathophysiology, Pathology, Capital Federal, Argentina
| | - F Fontana Estevez
- Pontifical Catholic University of Argentina, Biomedical Research Institute (BIOMED), Capital Federal, Argentina
| | - S Noli Truant
- University of Buenos Aires, Institute for studies of humoral immunity, Buenos Aires, Argentina
| | - V Miksztowicz
- University of Buenos Aires. Faculty of Pharmacy and Biochemistry, Lipids Laboratory, Capital Federal, Argentina
| | - A Cevey
- University of Buenos Aires, Institute of Biomedical Research in Retrovirus and Aids, Capital Federal, Argentina
| | - E Cicale
- University of Buenos Aires. Faculty of Veterinary, bioresources, Capital Federal, Argentina
| | - G Berg
- University of Buenos Aires. Faculty of Pharmacy and Biochemistry, Lipids Laboratory, Capital Federal, Argentina
| | - M Fernandez
- University of Buenos Aires, Institute for studies of humoral immunity, Buenos Aires, Argentina
| | - N Goren
- University of Buenos Aires, Institute of Biomedical Research in Retrovirus and Aids, Capital Federal, Argentina
| | - C Morales
- University of Buenos Aires-CONICET. Faculty of Medicine, Institute of Cardiovascular Pathophysiology, Pathology, Capital Federal, Argentina
| |
Collapse
|